CLYM116 (Anti-APRIL Antibody)

May 26, 2026 — Climb Bio, Inc. (Nasdaq: CLYM) announced it will present updates on two kidney-focused immunology programs at the European Renal Association (ERA) Congress 2026 (Glasgow, Scotland; June 3–6, 2026).

The company will give a focused oral presentation on CLYM116, a “sweeper” anti‑APRIL monoclonal antibody being developed for IgA nephropathy (IgAN), featuring pharmacokinetic/pharmacodynamic modeling translating nonhuman primate data to humans plus initial safety data from an ongoing Phase 1 study in healthy volunteers (Abstract #780; June 5, 2026).

Climb Bio will also present a trial‑in‑progress poster for PrisMN, its ongoing Phase 2 study of budoprutug (a low‑fucosylated anti‑CD19 monoclonal antibody) in primary membranous nephropathy (pMN) (Abstract #655; June 4–5, 2026).

Business/clinical significance: the presentations highlight early clinical safety for CLYM116 and ongoing mid‑stage development of budoprutug in pMN, supporting pipeline visibility and potential future efficacy readouts.